Luisa Fernanda Villaseñor

Dr. Luisa Fernanda Villaseñor


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
ARAna Paula Ruiz Lievano Ana Ruiz
Ana Paula Ruiz Lievano Ana Ruiz
FCFernando Cervantes-Flores
Fernando Cervantes-Flores
ATAlessandro Nava Torres
Alessandro Nava Torres
PMPaulo Javier Carbajal Morales
Paulo Javier Carbajal Morales
LVLuisa Fernanda Villaseñor
Luisa Fernanda Villaseñor
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
Community-acquired urinary tract infections account for 15% of all outpatient use of antibiotics, and women are primarily affected; the major causative microorganism is uropathogenic Escherichia coli (E. coli). Treatment is indicated for cystitis and pyelonephritis and includes B-lactams (amoxicillin-clavulanic acid or third-generation cephalosporins), fluoroquinolones (ciprofloxacin or levofloxacin), nitrofurantoin, fosfomycin, and trimethoprim–sulfamethoxazole. Resistance to antibiotic treatment is of concern; several mechanisms have been associated with the acquisition of genes that confer antimicrobial resistance to fluoroquinolones, which are often associated with other patterns of resistance, especially in extended-spectrum beta-lactamase (ESBL) producers. Several studies have addressed the prevalence of uropathogens producing ESBLs, but only a few have focused on fluoroquinolone resistance, and, to our knowledge, none have addressed the prevalence of phylotypes or genes responsible for antimicrobial resistance to fluoroquinolones. The focus of the present review was to analyze recently published papers that described the E. coli phylotype causing community-acquired UTIs in association with fluoroquinolone resistance.

25 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ARAna Paula Ruiz Lievano Ana Ruiz
Ana Paula Ruiz Lievano Ana Ruiz
FCFernando Cervantes-Flores
Fernando Cervantes-Flores
ATAlessandro Nava Torres
Alessandro Nava Torres
PMPaulo Javier Carbajal Morales
Paulo Javier Carbajal Morales
LVLuisa Fernanda Villaseñor
Luisa Fernanda Villaseñor
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
Community Acquired Urinary Tract Infections account for 15% of all outpatient use of antibiotics, women are primarily affected; major causative microorganisms are uro-pathogenic E. Coli. Treatment is indicated for cystitis and pyelonephritis and includes B-lactams (amoxicillin-clavulanic acid or third generation cephalosporins), fluoroquin-olones (ciprofloxacin or levofloxacin), nitrofurantoin, fosfomycin, and trime-thoprim-sulfamethoxazole. Resistance to antibiotic treatment is of concern, several mecha-nisms have been associated with the acquisition of genes that confer antimicrobial re-sistance to fluoroquinolones, which often are associated with other patterns of resistance, especially in extended spectrum beta lactases (ESBL) producers. Several studies have ad-dressed the prevalence of uropathogens producing ESBL, but only a few have focused on resistance against fluoroquinolones and to our knowledge, none has been addressing the prevalence of isolates mutations that confer antimicrobial resistance to fluoroquinolones. The focus of the present review was to analyze recent published papers that describe the E. coli phylotype causing community acquired UTIs in association to fluoroquinolones re-sistance.